Patient Relapse Time After Auto-HCT in Chemosensitive DLBCL Does Not Appear to Influence PFS
The data reinforce the need for direct comparison of CAR-T and autologous transplantation.
CAR-T Therapy
Deep and Durable Responses to Double Anti-BCMA, Single-Domain Antibody CAR-T Therapies Seen in RRMM
CAR-T therapy containing 2 anti-BCMA single-domain antibodies resulted in high response and PFS rates, according to phase 1b results.
Anti-BCMA CAR-T Deemed Effective in Heavily Pretreated, Refractory Multiple Myeloma
Anti-BCMA CAR T-cell therapy idecabtagene vicleucel demonstrated promising efficacy among patients with heavily pretreated and refractory MM.
Outpatient CAR-T Therapy May Offer Cost Savings, but More Data Are Needed
Administering CAR-T cell therapy in the outpatient community setting is estimated to save more than $30,000 per patient.
Novel Bispecific CD19/CD22 CAR-T Therapy Deemed Tolerable in Relapsed/Refractory ALL
A novel, bispecific CD19/CD22 CAR-T therapy was tolerable and led to responses in a phase 1, dose-escalating study.
What Factors Influence Hematological Recovery in Patients Who Receive CAR-T Therapies?
Two studies characterize hematological recovery after CAR-T cell therapy.
A First-in-Human Trial Offers Hope for CAR-T in Solid Tumors
CAR-T has seen most of its success in blood cancers, but a first-in-human trial of CAR-T in solid tumors is under way.
PI3K Inhibitors Increased T-Cell Expansion Ahead of CAR-T Cell Therapy
Concomitant use of inhibitors allowed for the manufacture of more potent T cells.
Immunoglobulin Replacement May Benefit Some Patients Receiving CAR-T Therapy
CAR-T therapy can sometimes lead to immune system dysfunction, subsequent hypogammaglobulinemia, and the need for antibody replacement therapy.
BELINDA Trial Tests Earlier Use of Tisa-Cel in Aggressive B-Cell Non-Hodgkin Lymphoma
Bumping CAR-T cell therapy earlier in the treatment protocol could reduce toxicity and improve survival for patients with relapsed or refractory disease.
Next post in Lymphoma
